Navigation Links
Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
Date:5/6/2008

TORONTO, May 6 /PRNewswire/ - Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.

Utilizing enzyme-based technology developed at Thermo Fisher Scientific's Milwaukee, Wisconsin, molecular bioreagents facility, Dalton will produce poly-inosine (poly-I) and poly-cytosine (poly-C) in accordance with cGMP (current good manufacturing practice) regulations. Poly-I and Poly-C are polynucleotides that are used as adjuvants, or catalysts, to stimulate an immune response when combined with other substances in a drug. Dalton will supply these polynucleotides to Oncovir, Inc., an innovative pharmaceutical company that will use Poly-I and Poly-C in vaccine development.

"We are delighted to have this opportunity to work with Thermo Fisher Scientific in order to commercialize their novel biopolymers," said Peter Pekos, president and CEO of Dalton Pharma Services. "The agreement is timely due to an increased demand for commercial quantities of these molecules as adjuvants for new vaccines. And, this partnership recognizes Dalton's expertise in cGMP manufacturing and analysis of complex molecules under cGMP conditions."

"By working with partners like Dalton Pharma Services, our innovative technology is finding its way into new and exciting therapeutics," said Mitch Kennedy, global vice president and general manager of Thermo Fisher Scientific's Genomics business. "Ultimately, this allows Thermo Fisher Scientific to advance our mission as a company, which is to enable our customers to make the world healthier, cleaner and safer."

About Dalton Pharma Services

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analyt
'/>"/>

SOURCE Dalton Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
2. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
4. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Benda Pharmaceutical Files Amendment To Form S-1
6. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
7. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
8. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
9. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 13Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 14Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 15Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 16Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 17Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables 18Jivan Focuses on Solutions for Transcriptome Sequencing 2X marks the spot: Ions coldly go through NIST trap junction 2